These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 38602614)

  • 1. No prognostic impact of staging bone scan in patients with stage IA non-small cell lung cancer.
    Zheng X; Li C; Ai J; Dong G; Long M; Li M; Qiu S; Huang Y; Yang G; Zhang T; Li Z
    Ann Nucl Med; 2024 Jul; 38(7):534-543. PubMed ID: 38602614
    [TBL] [Abstract][Full Text] [Related]  

  • 2. No Prognostic Impact of Staging Brain MRI in Patients with Stage IA Non-Small Cell Lung Cancer.
    Nam JG; Hong H; Choi SH; Park CM; Goo JM; Kim YT; Kim H
    Radiology; 2022 Jun; 303(3):632-643. PubMed ID: 35258373
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sublobar Resection in Stage IA Non-Small Cell Lung Cancer: Role of Preoperative CT Features in Predicting Pathologic Lymphovascular Invasion and Postoperative Recurrence.
    Choe J; Kim MY; Yun JK; Lee GD; Kim YH; Choi S; Kim DK
    AJR Am J Roentgenol; 2021 Oct; 217(4):871-881. PubMed ID: 33978462
    [No Abstract]   [Full Text] [Related]  

  • 4. Comparison of prognostic impact of lymphovascular invasion in stage IA non-small cell lung cancer after lobectomy versus sublobar resection: A propensity score-matched analysis.
    Yun JK; Lee GD; Choi S; Kim HR; Kim YH; Kim DK; Park SI
    Lung Cancer; 2020 Aug; 146():105-111. PubMed ID: 32526600
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk factor analysis of locoregional recurrence after sublobar resection in patients with clinical stage IA non-small cell lung cancer.
    Koike T; Koike T; Yoshiya K; Tsuchida M; Toyabe S
    J Thorac Cardiovasc Surg; 2013 Aug; 146(2):372-8. PubMed ID: 23870323
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nomograms for Predicting Overall and Recurrence-free Survival From Pathologic Stage IA and IB Lung Cancer After Lobectomy.
    Merritt RE; Abdel-Rasoul M; Fitzgerald M; D'Souza DM; Kneuertz PJ
    Clin Lung Cancer; 2021 Jul; 22(4):e574-e583. PubMed ID: 33234491
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of whole-body bone scanning and clinical factors in detecting bone metastases in patients with non-small cell lung cancer.
    Erturan S; Yaman M; Aydin G; Uzel I; Müsellim B; Kaynak K
    Chest; 2005 Feb; 127(2):449-54. PubMed ID: 15705981
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic Effect of Lymphovascular Invasion on TNM Staging in Stage I Non-Small-cell Lung Cancer.
    Noma D; Inamura K; Matsuura Y; Hirata Y; Nakajima T; Yamazaki H; Hirai Y; Ichinose J; Nakao M; Ninomiya H; Mun M; Nakagawa K; Masuda M; Ishikawa Y; Okumura S
    Clin Lung Cancer; 2018 Jan; 19(1):e109-e122. PubMed ID: 29066222
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PET scan 18F-fluorodeoxyglucose uptake and prognosis in patients with resected clinical stage IA non-small cell lung cancer.
    Nair VS; Barnett PG; Ananth L; Gould MK;
    Chest; 2010 May; 137(5):1150-6. PubMed ID: 20038738
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of abnormal uptakes in bone scan on the prognosis of patients with lung cancer.
    Park JY; Kim KY; Lee J; Kam S; Son JW; Kim CH; Jung TH
    Lung Cancer; 2000 Apr; 28(1):55-62. PubMed ID: 10704710
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bone marrow micrometastasis is associated with both disease recurrence and poor survival in surgical patients with node-negative non-small-cell lung cancer: a meta-analysis.
    Deng XF; Liu QX; Zhou D; Min JX; Dai JG
    Interact Cardiovasc Thorac Surg; 2015 Jul; 21(1):21-7. PubMed ID: 25883247
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-Term Results for Clinical Stage IA Lung Cancer: Comparing Lobectomy and Sublobar Resection.
    Subramanian M; McMurry T; Meyers BF; Puri V; Kozower BD
    Ann Thorac Surg; 2018 Aug; 106(2):375-381. PubMed ID: 29580779
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic value of positron emission tomography in resected stage IA non-small cell lung cancer.
    Chou HP; Lin KH; Huang HK; Lin LF; Chen YY; Wu TH; Lee SC; Chang H; Huang TW
    Eur Radiol; 2021 Oct; 31(10):8021-8029. PubMed ID: 33763721
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Prognosis after complete surgical resection for non-small cell lung cancer based on the staging classification].
    Pfannschmidt J; Muley T; Hoffmann H; Bülzebruck H; Dienemann H
    Dtsch Med Wochenschr; 2006 Nov; 131(47):2643-8. PubMed ID: 17109272
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preoperative identification of clinicopathological prognostic factors for relapse-free survival in clinical N1 non-small cell lung cancer: a retrospective single center-based study.
    Aragaki M; Kato T; Fujiwara-Kuroda A; Hida Y; Kaga K; Wakasa S
    J Cardiothorac Surg; 2020 Aug; 15(1):229. PubMed ID: 32859238
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Revisiting the prognostic value of preoperative (18)F-fluoro-2-deoxyglucose ( (18)F-FDG) positron emission tomography (PET) in early-stage (I & II) non-small cell lung cancers (NSCLC).
    Agarwal M; Brahmanday G; Bajaj SK; Ravikrishnan KP; Wong CY
    Eur J Nucl Med Mol Imaging; 2010 Apr; 37(4):691-8. PubMed ID: 19915840
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of FDG PET Standardized Uptake Value in Resected Clinical Stage IA Non-Small Cell Lung Cancer.
    Tapias LF; Shen R; Cassivi SD; Reisenauer JS; Lunn BW; Lechtenberg BJ; Nichols FC; Wigle DA; Blackmon SH
    Ann Thorac Surg; 2024 May; 117(5):1017-1023. PubMed ID: 37080373
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of preoperative [
    Lin JT; Li XM; Zhong WZ; Hou QY; Liu CL; Yu XY; Ye KY; Cheng YL; Du JY; Sun YQ; Zhang FG; Yan HH; Liao RQ; Dong S; Jiang BY; Liu SY; Wu YL; Yang XN
    Ann Nucl Med; 2024 Mar; 38(3):188-198. PubMed ID: 38145431
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical impact of a small component of ground-glass opacity in solid-dominant clinical stage IA non-small cell lung cancer.
    Watanabe Y; Hattori A; Nojiri S; Matsunaga T; Takamochi K; Oh S; Suzuki K
    J Thorac Cardiovasc Surg; 2022 Mar; 163(3):791-801.e4. PubMed ID: 33516459
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic value of adjuvant therapy in T4 non-small cell lung cancer: An inverse probability of treatment weighting analysis.
    Song YT; Yang SL; Fu Z; Liu XH; Yan SY; Wang ZH; Qin TT; Jiang HW; Jin Y; Yin P
    Thorac Cancer; 2019 Mar; 10(3):472-482. PubMed ID: 30628189
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.